Skip to content
Screener

Solid Biosciences Inc. SLDB Internal General And Administrative Expense — General And Administrative Expense

Other product segments

External General And Administrative Expense
$6.33M+19.9%

Similar metrics at other companies

AnaptysBio, Inc. logo
ANABInternal Expenses — General And Administrative Expense
$14.08M+63.9%
Beam Therapeutics logo
BEAMExternal General And Administrative Expenses — General And Administrative Expense
$13.37M+149%
TRA
TRAXExternal Expenses — General And Administrative Expense
$8.72M+127%
AnaptysBio, Inc. logo
ANABExternal Expenses — General And Administrative Expense
$12.12M+119%
TRA
TRAXInternal Expense — General And Administrative Expense
$10.14M+69.9%
Rein Therapeutics Inc. logo
RNTXEmployee Related Expenses — General And Administrative Expense
$859K-9.3%

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.4M-37.6%
Net income-$54.8M-38.8%
EPS (diluted)-$0.38+9.5%

Balance sheet

See full
Cash & equivalents$159.4M+14.7%
Total debt$20.2M-12.6%
Total equity$374.1M+44.8%
Total assets$420.6M+36.4%

Cash flow

See full
Operating cash flow-$52.6M-40.6%
CapEx$150.0K-60.2%
Free cash flow-$52.7M-39.6%

Valuation

See full
Market cap$857.5M+90.9%
Enterprise value$718.26M+114%

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-65.5%-2.5pp
Debt / equity0.1×0.0×
Current ratio13.8×+4.5×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337935
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
SGT-2122,3641,1455,6801,970
External R&D other1,9833,1164,8405,886
Internal R&D expense(1)9,0606,76518,21113,608
External G&A expense6,3275,27911,79510,156
Internal G&A expense(1)4,7343,3608,6006,823
Other segment items(2)7,4977,58615,79815,228
Other income, net(2,585)(2,213)(3,156)(2,983)
Condensed consolidated net loss$(54,799)$(39,480)$(111,536)$(78,762)

Item 1. Financial Statements (unaudited)

FAQ

What is Solid Biosciences Inc.'s internal general and administrative expense — general and administrative expense?
Solid Biosciences Inc. (SLDB) reported internal general and administrative expense — general and administrative expense of $4.73M in Q2 2026.
How has Solid Biosciences Inc.'s internal general and administrative expense — general and administrative expense changed year-over-year?
Solid Biosciences Inc.'s internal general and administrative expense — general and administrative expense increased by 40.9% year-over-year, from $3.36M to $4.73M.
What is the long-term trend for Solid Biosciences Inc.'s internal general and administrative expense — general and administrative expense?
Over 2 years (2023 to 2025), Solid Biosciences Inc.'s internal general and administrative expense — general and administrative expense has grown at a 13.1% compound annual growth rate (CAGR), from $10.91M to $13.96M.
What does internal general and administrative expense — general and administrative expense mean?
This metric represents the operating costs incurred by the company to support its internal administrative functions, such as executive management, legal, finance, and human resources. It reflects the overhead required to sustain corporate operations and infrastructure independent of direct research and development activities. Monitoring this expense helps investors evaluate the company's operational efficiency and the scalability of its corporate support structure.

Ask your AI about Solid Biosciences Inc.'s internal general and administrative expense — general and administrative expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude